Medicinal Chemistry of Oligonucleotide Drugs - Milestones of the Past and Visions for the Future

Authors

DOI:

https://doi.org/10.2533/chimia.2022.466

PMID:

38069719

Keywords:

Antisense, Gapmer, Oligonucleotide, Small interfering RNA

Abstract

The oligonucleotide therapeutics field has blossomed in recent years, with thirteen approved drugs today and the promise of accelerated growth in coming years. Much of the progress in this field is due to advances in the medicinal chemistry of oligonucleotides,combined with a judicious choice of molecular targets and disease areas. In this perspective, we describe the growth of this new class of drugs highlighting selected milestones in oligonucleotide medicinal chemistry.

Funding data

CHIMIA Vol. 76 No. 5 (2022): Medicinal Chemistry

Downloads

Published

2022-05-25

Issue

Vol. 76 No. 5 (2022): Medicinal Chemistry

Section

Scientific Articles

License

Copyright (c) 2022 Jonathan Hall, Anastasia Ashkinadze, Jan Philipp Becker, Artur Laski, Eva-Maria Manz, Štefan Moravčík, Sebastian Sjöström, Mathilde Vincent

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

How to Cite

[1]
J. Hall, A. Ashkinadze, J. P. Becker, A. Laski, E.-M. Manz, Štefan Moravčík, S. Sjöström, M. Vincent, Chimia 2022, 76, 466, DOI: 10.2533/chimia.2022.466.